IBDEI2VK ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45859,0)
 ;;=I48.0^^173^2287^7
 ;;^UTILITY(U,$J,358.3,45859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45859,1,3,0)
 ;;=3^Atrial Fibrillation,Paroxysmal
 ;;^UTILITY(U,$J,358.3,45859,1,4,0)
 ;;=4^I48.0
 ;;^UTILITY(U,$J,358.3,45859,2)
 ;;=^90473
 ;;^UTILITY(U,$J,358.3,45860,0)
 ;;=Z86.711^^173^2287^17
 ;;^UTILITY(U,$J,358.3,45860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45860,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,45860,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,45860,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,45861,0)
 ;;=Z95.2^^173^2287^18
 ;;^UTILITY(U,$J,358.3,45861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45861,1,3,0)
 ;;=3^Presence of Prosthetic Heart Valve
 ;;^UTILITY(U,$J,358.3,45861,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,45861,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,45862,0)
 ;;=I48.92^^173^2287^9
 ;;^UTILITY(U,$J,358.3,45862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45862,1,3,0)
 ;;=3^Atrial Flutter,Unspec
 ;;^UTILITY(U,$J,358.3,45862,1,4,0)
 ;;=4^I48.92
 ;;^UTILITY(U,$J,358.3,45862,2)
 ;;=^5007230
 ;;^UTILITY(U,$J,358.3,45863,0)
 ;;=D68.8^^173^2287^11
 ;;^UTILITY(U,$J,358.3,45863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45863,1,3,0)
 ;;=3^Coagulation Defects,Oth Specified
 ;;^UTILITY(U,$J,358.3,45863,1,4,0)
 ;;=4^D68.8
 ;;^UTILITY(U,$J,358.3,45863,2)
 ;;=^5002363
 ;;^UTILITY(U,$J,358.3,45864,0)
 ;;=D68.318^^173^2287^13
 ;;^UTILITY(U,$J,358.3,45864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45864,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrns Circ Anticoag/Antib/Inhib
 ;;^UTILITY(U,$J,358.3,45864,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,45864,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,45865,0)
 ;;=D68.32^^173^2287^12
 ;;^UTILITY(U,$J,358.3,45865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45865,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,45865,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,45865,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,45866,0)
 ;;=I10.^^173^2287^14
 ;;^UTILITY(U,$J,358.3,45866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45866,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,45866,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,45866,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,45867,0)
 ;;=I82.401^^173^2287^3
 ;;^UTILITY(U,$J,358.3,45867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45867,1,3,0)
 ;;=3^Acute Embolism/Thrombos Deep Veins,Rt Lower Extrem,Unspec
 ;;^UTILITY(U,$J,358.3,45867,1,4,0)
 ;;=4^I82.401
 ;;^UTILITY(U,$J,358.3,45867,2)
 ;;=^5007854
 ;;^UTILITY(U,$J,358.3,45868,0)
 ;;=I82.402^^173^2287^2
 ;;^UTILITY(U,$J,358.3,45868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45868,1,3,0)
 ;;=3^Acute Embolism/Thrombos Deep Veins,Lt Lower Extrem,Unspec
 ;;^UTILITY(U,$J,358.3,45868,1,4,0)
 ;;=4^I82.402
 ;;^UTILITY(U,$J,358.3,45868,2)
 ;;=^5007855
 ;;^UTILITY(U,$J,358.3,45869,0)
 ;;=I82.890^^173^2287^1
 ;;^UTILITY(U,$J,358.3,45869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45869,1,3,0)
 ;;=3^Acute Embolism/Thromb of Other Specified Veins
 ;;^UTILITY(U,$J,358.3,45869,1,4,0)
 ;;=4^I82.890
 ;;^UTILITY(U,$J,358.3,45869,2)
 ;;=^5007938
 ;;^UTILITY(U,$J,358.3,45870,0)
 ;;=I82.891^^173^2287^10
 ;;^UTILITY(U,$J,358.3,45870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45870,1,3,0)
 ;;=3^Chronic Embolism/Thrombo of Other Specified Veins
 ;;^UTILITY(U,$J,358.3,45870,1,4,0)
 ;;=4^I82.891
